Durvalumab (D) ± tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

Özgüroğlu M.

Annals of Oncology, vol.1, no.1, pp.1, 2020 (Conference Book)

• Publication Type: Article / Article
• Volume: 1 Issue: 1
• Publication Date: 2020
• Doi Number: 10.1016/j.annonc.2020.10.373
• Journal Name: Annals of Oncology
• Page Numbers: pp.1
• Istanbul University-Cerrahpasa Affiliated: No